|

Supplements and APOE ε4: DHA, Vitamins, and What the Evidence Really Shows

Patient & Family Guide · Nutrition · Supplements

Supplements and APOE ε4: DHA, Vitamins, and What the Evidence Really Shows

By Brian Paquette, DO, MPH

Board-Certified Neurologist · APOE ε4 Carrier · Evidence reviewed October 22, 2026 · Free to read

No supplement has been proven to prevent or slow Alzheimer’s disease in people who carry APOE ε4. This guide explains which supplements are worth discussing with your doctor, which are not, and why. It covers carriers who have no symptoms as well as people already living with Alzheimer’s dementia.

Summary of Recommendations

The short answer: eat fish regularly, correct any vitamin deficiency your doctor finds, and be skeptical of “brain supplements.” Exercise, sleep, and control of blood pressure, cholesterol, and blood sugar have stronger evidence than any pill.

Strong reasons to do this

Recommended

  • Eat fish at least twice a week, including fatty, lower-mercury fish such as salmon, sardines, or trout. It is good for the heart, and studies link it with slower memory decline in ε4 carriers.
  • Treat a confirmed vitamin deficiency. If a blood test shows low vitamin B12, folate, or another vitamin, correcting it protects the nerves and blood. It is good medicine, but it is not a treatment for Alzheimer’s disease.

Limited or uncertain evidence

Discuss with your doctor first

  • A DHA (omega-3) supplement if you rarely eat fish. It is reasonable to consider but has not been proven to prevent memory loss, including in ε4 carriers.
  • Vitamin E (2,000 IU a day), only for people already diagnosed with mild to moderate Alzheimer’s dementia and only under a doctor’s supervision. It modestly slowed the loss of everyday abilities in one major trial, without improving memory.
  • Souvenaid (a medical nutrition drink) and MCT oil. Results are mixed. MCT oil appears to help ε4 carriers less than non-carriers and often upsets the stomach.

Little benefit or possible harm

Not recommended for brain health

  • High-dose vitamin B6 or “megadose” B-complex. Did not slow Alzheimer’s disease, and too much B6 can damage nerves.
  • High-dose vitamin E on your own. It carries a small risk of bleeding into the brain.
  • DHA or fish oil as a treatment for established dementia. Large trials found no benefit, including in ε4 carriers.
  • Ginkgo, huperzine A, curcumin (turmeric), resveratrol, and “memory blends.” Clinical trials have not shown that they prevent or slow Alzheimer’s disease.

What about APOE ε4 specifically? Where studies have looked at genotype, no supplement has shown a special benefit for ε4 carriers. In two cases (DHA in established dementia and MCT oil), the small benefits that were seen appeared in non-carriers. Being a carrier is not, by itself, a reason to take a supplement.

Key terms in plain language

  • Randomized trial: people are assigned by chance to a supplement or a placebo (a look-alike with no active ingredient). This is the best way to tell whether a supplement itself makes a difference.
  • Observational study: researchers follow people and compare those who happen to eat or take something with those who do not. These studies can show a link but cannot prove cause and effect.
  • MCI (mild cognitive impairment): memory or thinking problems that are noticeable but do not yet interfere with daily independence.

DHA and Fish Oil

DHA (docosahexaenoic acid) is an omega-3 fat found mainly in fatty fish, seafood, and algae. It is one of the main building blocks of brain cell membranes. Because laboratory and animal research suggested that APOE ε4 may change how the brain handles DHA, researchers have asked whether ε4 carriers in particular might benefit from getting more of it (Yassine et al., JAMA Neurology 2017).

What the studies show

  • Observational studies are encouraging. In the Rush Memory and Aging Project (915 older adults), eating seafood at least weekly was linked to slower decline in ε4 carriers but not in non-carriers (van de Rest et al., Neurology 2016). In a 10-year study of 1,670 older adults, long-term omega-3 supplement use was linked to lower Alzheimer’s risk only in ε4 carriers (Li et al., Eur J Neurol 2022). Pooling 48 long-term studies, higher dietary omega-3 intake was linked to about 20 percent lower risk of dementia or cognitive decline (Wei et al., Am J Clin Nutr 2023).
  • The first ε4-focused prevention trial did not show a memory benefit. In PreventE4, 365 adults aged 55 to 80 without dementia (about half ε4 carriers) took 2 grams of DHA daily or a placebo for two years. DHA reached the brain’s fluid equally well in carriers and non-carriers, but memory, thinking, and brain volume did not differ between groups. The trial was designed mainly to test whether DHA reached the brain, and 38 percent of participants dropped out, largely because of COVID-19, so a small benefit cannot be ruled out (Yassine et al., eBioMedicine 2026).
  • Once Alzheimer’s dementia has developed, DHA has not helped. In a trial of 402 people with mild to moderate Alzheimer’s disease, 2 grams of DHA daily for 18 months did not slow decline (Quinn et al., JAMA 2010). An exploratory analysis found no effect in ε4 carriers; any possible benefit was limited to non-carriers and was not confirmed. A Cochrane review reached the same overall conclusion (Burckhardt et al., 2016).
  • Across all trials, omega-3 supplements had little or no effect on developing dementia or cognitive decline (38 trials, nearly 50,000 people; Brainard et al., J Am Med Dir Assoc 2020).

Why fish and capsules give different answers. Fish is part of a whole diet. It supplies protein, vitamin D, and other nutrients and often replaces less healthy foods. People who eat more fish also tend to differ in other healthy ways. That is why studies of fish eaters look favorable while supplement trials have mostly been negative.

If you choose to take DHA

  • Talk with your doctor about the dose. PreventE4 used 2 grams a day, but no dose has been shown to prevent Alzheimer’s disease.
  • Check the actual DHA content on the label, not the total “fish oil” amount, and choose a product with independent third-party testing.
  • Algal DHA comes from algae rather than fish, suits vegetarians and vegans, and was the form used in the Alzheimer’s dementia trial.
  • Heart rhythm. In large heart trials, omega-3 supplements were linked to a higher risk of atrial fibrillation, an irregular heartbeat: about 12 percent higher at 1 gram a day or less and about 49 percent higher above 1 gram (Gencer et al., Circulation 2021). Eating fish does not appear to carry this risk; higher omega-3 blood levels from usual diets were not linked to atrial fibrillation (Qian et al., J Am Coll Cardiol 2023).
  • Bleeding. Across 11 trials of more than 120,000 people, omega-3 supplements did not increase overall bleeding (Javaid et al., J Am Heart Assoc 2024). Still, tell your doctor about every supplement you take, especially before surgery or if you take a blood thinner.

APOE4 Insights accepts no supplement sponsorship or affiliate payments and does not recommend specific brands.

Vitamin E

Vitamin E has the strongest treatment signal of any common supplement, but only for people who already have Alzheimer’s dementia, and the benefit is modest.

  • The main trial. In TEAM-AD, 613 people with mild to moderate Alzheimer’s disease at 14 Veterans Affairs medical centers, all taking a standard Alzheimer’s medicine, received vitamin E 2,000 IU a day or a placebo. Over about two years, those on vitamin E lost everyday abilities more slowly, equal to a delay of about six months, and caregiver time rose less (Dysken et al., JAMA 2014). An earlier trial in more advanced disease also suggested a delay in decline (Sano et al., NEJM 1997).
  • No memory benefit, no prevention. A Cochrane review found that vitamin E did not improve memory or thinking in Alzheimer’s disease and did not prevent people with MCI from progressing to dementia (Farina et al., 2017).
  • Safety. In the Alzheimer’s trials, vitamin E did not increase serious side effects or deaths (Farina et al., 2017). Across trials in other groups, however, doses of 400 IU a day or more were linked to a small increase in deaths, about 39 extra deaths per 10,000 people, although many of those trials involved people with chronic illness (Miller et al., Ann Intern Med 2005). Vitamin E was also linked to a small increase in bleeding strokes, about one extra case for every 1,250 people taking it (Schürks et al., BMJ 2010).
  • No ε4-specific benefit has been shown.

Bottom line: vitamin E is a reasonable option to discuss for someone with diagnosed mild to moderate Alzheimer’s dementia, but only with their physician, who can weigh it against bleeding risk and other medicines. It is not recommended for prevention.

B Vitamins

  • Treat a true deficiency. A low vitamin B12 (or folate, or another vitamin) found on a blood test should be corrected, because deficiency can damage nerves and blood cells. Correcting it is unlikely to reverse established Alzheimer’s dementia: in a Danish study of more than 50,000 people, low B12 levels and B12 treatment were not linked to the risk of Alzheimer’s disease (Arendt et al., J Alzheimers Dis 2021).
  • Extra B vitamins do not help when levels are normal. In a trial of 409 people with Alzheimer’s disease and normal vitamin levels, high-dose folate, B6, and B12 for 18 months lowered homocysteine but did not slow decline, and depression-related side effects were more common (Aisen et al., JAMA 2008).
  • Avoid high-dose vitamin B6. Too much B6 (pyridoxine), often hidden in “energy” or B-complex products, can damage the sensory nerves and cause numbness or tingling in the hands and feet (Hadtstein and Vrolijk, Adv Nutr 2021).

Other Popular Supplements

  • Souvenaid (Fortasyn Connect). In LipiDiDiet, people with very early (prodromal) Alzheimer’s disease showed no benefit on the main outcome at two years (Soininen et al., Lancet Neurol 2017). A three-year analysis reported slower decline, but only 81 participants contributed final-year data (Soininen et al., Alzheimers Dement 2021). A Cochrane review concluded that it probably does not reduce progression to dementia and that any improvement was below what patients would notice (Burckhardt et al., 2020).
  • MCT oil (medium-chain triglycerides). In the original trial, the benefit was seen mainly in people without ε4 (Henderson et al., Nutr Metab 2009), and a 2023 meta-analysis confirmed a larger effect in non-carriers (Sun et al., J Alzheimers Dis 2023). One small, one-month crossover trial in mostly ε4 carriers did report improvement (Xu et al., Clin Nutr 2020). Diarrhea and stomach upset are common.
  • Ginkgo biloba. In a trial of 3,069 adults aged 75 and older followed for about six years, ginkgo did not reduce the rate of dementia or Alzheimer’s disease (DeKosky et al., JAMA 2008).
  • Huperzine A. In a US trial of 210 people with Alzheimer’s disease, the main dose did not improve thinking (Rafii et al., Neurology 2011). It acts like prescription Alzheimer’s medicines, so it should not be combined with them without medical advice.
  • Curcumin and resveratrol. A 24-week curcumin trial showed no clinical or biomarker benefit and very low absorption (Ringman et al., Alzheimers Res Ther 2012). A one-year resveratrol trial was not designed to show clinical benefit, and brain volume loss was greater on resveratrol than on placebo (Turner et al., Neurology 2015).
  • “Memory blends.” Multi-ingredient products marketed for memory have not been shown in rigorous trials to prevent or slow Alzheimer’s disease.

Evidence at a Glance

Summary of the evidence for common supplements, by stage
Supplement Best evidence Verdict
Fish in the diet Observational studies; heart guidance (Rimm et al., 2018) Recommended
B12 or other vitamin, if deficient Standard medical care Treat deficiency
DHA supplement, before symptoms One randomized trial: no memory benefit Optional; unproven
Vitamin E, diagnosed dementia Two randomized trials: slower loss of daily function Doctor-supervised only
Souvenaid, MCT oil Mixed trials; MCT less effective in ε4 Uncertain
DHA, established dementia Randomized trial and Cochrane review: no benefit Not recommended
High-dose B vitamins, normal levels Randomized trial: no benefit Not recommended
Ginkgo, huperzine A, curcumin, resveratrol Randomized trials: no benefit shown Not recommended

Simple Steps

  1. Eat fish at least twice a week, preferably including fatty, lower-mercury fish.
  2. Ask your doctor whether your vitamin B12 and other levels should be checked, and treat any deficiency found.
  3. If you rarely eat fish and want a DHA supplement, choose a third-party tested product and agree on a dose with your doctor, especially if you have heart rhythm problems.
  4. If you or a family member has Alzheimer’s dementia, ask the treating physician whether vitamin E is appropriate. Do not start high-dose vitamin E on your own.
  5. Skip high-dose B6 and “memory” products, and tell your clinicians about every supplement you use.
  6. Put your effort where the evidence is strongest: exercise, sleep, hearing, and control of blood pressure, cholesterol, and blood sugar.

Limitations

Most supplement trials were small, short, or tested a single dose. Few analyzed results by APOE genotype, and those that did usually treated genotype as an exploratory subgroup. Observational studies of fish and omega-3 intake cannot separate the effect of the food from the healthier habits of the people who eat it. The vitamin E safety data come largely from trials in people with heart disease and other chronic illnesses. This guide does not cover prescription Alzheimer’s treatments.

References

  1. Yassine HN, Pour SG, Juarez M, et al. CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial. eBioMedicine. 2026;129:106316. doi:10.1016/j.ebiom.2026.106316. PMID: 42315445
  2. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010;304(17):1903-1911. doi:10.1001/jama.2010.1510. PMID: 21045096
  3. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev. 2016;4:CD009002. doi:10.1002/14651858.CD009002.pub3. PMID: 27063583
  4. Brainard JS, Jimoh OF, Deane KHO, et al. Omega-3, omega-6, and polyunsaturated fat for cognition: systematic review and meta-analysis of randomized trials. J Am Med Dir Assoc. 2020;21(10):1439-1450.e21. doi:10.1016/j.jamda.2020.02.022. PMID: 32305302
  5. van de Rest O, Wang Y, Barnes LL, et al. APOE ε4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Neurology. 2016;86(22):2063-2070. doi:10.1212/WNL.0000000000002719. PMID: 27164694
  6. Li L, Xu W, Tan CC, et al. A gene-environment interplay between omega-3 supplementation and APOE ε4 provides insights for Alzheimer’s disease precise prevention amongst high-genetic-risk population. Eur J Neurol. 2022;29(2):422-431. doi:10.1111/ene.15160. PMID: 34710256
  7. Wei BZ, Li L, Dong CW, et al. The relationship of omega-3 fatty acids with dementia and cognitive decline: evidence from prospective cohort studies of supplementation, dietary intake, and blood markers. Am J Clin Nutr. 2023;117(6):1096-1109. doi:10.1016/j.ajcnut.2023.04.001. PMID: 37028557
  8. Yassine HN, Braskie MN, Mack WJ, et al. Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers: a review. JAMA Neurol. 2017;74(3):339-347. doi:10.1001/jamaneurol.2016.4899. PMID: 28114437
  9. Rimm EB, Appel LJ, Chiuve SE, et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2018;138(1):e35-e47. doi:10.1161/CIR.0000000000000574. PMID: 29773586
  10. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-1990. doi:10.1161/CIRCULATIONAHA.121.055654. PMID: 34612056
  11. Qian F, Tintle N, Jensen PN, et al. Omega-3 fatty acid biomarkers and incident atrial fibrillation. J Am Coll Cardiol. 2023;82(4):336-349. doi:10.1016/j.jacc.2023.05.024. PMID: 37468189
  12. Javaid M, Kadhim K, Bawamia B, et al. Bleeding risk in patients receiving omega-3 polyunsaturated fatty acids: a systematic review and meta-analysis of randomized clinical trials. J Am Heart Assoc. 2024;13(10):e032390. doi:10.1161/JAHA.123.032390. PMID: 38742535
  13. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014;311(1):33-44. doi:10.1001/jama.2013.282834. PMID: 24381967
  14. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med. 1997;336(17):1216-1222. doi:10.1056/NEJM199704243361704. PMID: 9110909
  15. Farina N, Llewellyn D, Isaac MGEKN, Tabet N. Vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017;1:CD002854. doi:10.1002/14651858.CD002854.pub4. PMID: 28128435
  16. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46. doi:10.7326/0003-4819-142-1-200501040-00110. PMID: 15537682
  17. Schürks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ. 2010;341:c5702. doi:10.1136/bmj.c5702. PMID: 21051774
  18. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774-1783. doi:10.1001/jama.300.15.1774. PMID: 18854539
  19. Arendt JFH, Horváth-Puhó E, Sørensen HT, et al. Plasma vitamin B12 levels, high-dose vitamin B12 treatment, and risk of dementia. J Alzheimers Dis. 2021;79(4):1601-1612. doi:10.3233/JAD-201096. PMID: 33459639
  20. Hadtstein F, Vrolijk M. Vitamin B-6-induced neuropathy: exploring the mechanisms of pyridoxine toxicity. Adv Nutr. 2021;12(5):1911-1929. doi:10.1093/advances/nmab033. PMID: 33912895
  21. Soininen H, Solomon A, Visser PJ, et al. 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(12):965-975. doi:10.1016/S1474-4422(17)30332-0. PMID: 29097166
  22. Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimers Dement. 2021;17(1):29-40. doi:10.1002/alz.12172. PMID: 32920957
  23. Burckhardt M, Watzke S, Wienke A, Langer G, Fink A. Souvenaid for Alzheimer’s disease. Cochrane Database Syst Rev. 2020;12:CD011679. doi:10.1002/14651858.CD011679.pub2. PMID: 33320335
  24. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;6:31. doi:10.1186/1743-7075-6-31. PMID: 19664276
  25. Xu Q, Zhang Y, Zhang X, et al. Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer’s disease patients with APOE4: a double-blind, randomized, placebo-controlled crossover trial. Clin Nutr. 2020;39(7):2092-2105. doi:10.1016/j.clnu.2019.10.017. PMID: 31694759
  26. Sun L, Ye KX, Wong HLK, et al. The effects of medium chain triglyceride for Alzheimer’s disease related cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis. 2023;94(2):441-456. doi:10.3233/JAD-230406. PMID: 37248908
  27. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262. doi:10.1001/jama.2008.683. PMID: 19017911
  28. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389-1394. doi:10.1212/WNL.0b013e318216eb7b. PMID: 21502597
  29. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4(5):43. doi:10.1186/alzrt146. PMID: 23107780
  30. Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85(16):1383-1391. doi:10.1212/WNL.0000000000002035. PMID: 26362286

EDITORIAL NOTE: All citations were verified against the PubMed record on October 22, 2026. This guide replaces two earlier articles, a patient DHA guide and a clinician DHA framework, and adds vitamin E, B vitamins, and other supplements. APOE4 Insights accepts no supplement sponsorship or affiliate payments. Educational content only; not a substitute for individual medical advice.

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Just learned you carry APOE4?

Get the free physician’s guide Your First 30 Days After an APOE4 Result, plus one evidence update a month.

No spam. Unsubscribe anytime.

Similar Posts